Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

The list includes Novo Nordisk’s blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, ...

Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on January 13 and set a price target of ...

In a report released today, Florent Cespedes from Bernstein maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

Brookstone Capital Management cut its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 9.9% in the fourth quarter, ...

Medicare will seek to negotiate lower prices for Novo Nordisk's popular but pricey GLP-1 drugs Ozempic, Wegovy and Rybelsus, ...